| Name | Title | Contact Details |
|---|
POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
AQP - Affordable Quality Pharmaceuticals, Inc. is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.